Trial Profile

An Open-label Multicenter Study on the Efficacy of Continuous Oral Dosing of Vemurafenib on Tumour Response in Previously Treated Patients With Metastatic Melanoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 Apr 2021 Results (N=898) of a pooled analysis of data from 3 studies BRIM-2, BRIM-3 and coBRIM study assessing relationship between vemurafenib exposure, as measured by the estimated apparent clearance at steady state and any grade more than or equal to 3 toxicity published in the Journal of Clinical Pharmacology
16 Aug 2019 Results of a pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM studies assessing the impact of depth of response on survival in patients treated with cobimetinib +/- vemurafenib, published in the British Journal of Cancer
04 Jun 2019 Results of pooled analysis for patients treated with vemurafenib or cobimetinib plus vemurafenib in the BRIM-2, BRIM-3, BRIM-7, and coBRIM studies published in the European Journal of Cancer

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com